Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANGNNASDAQ:GMTXNASDAQ:NEXINASDAQ:SGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANGNAngion Biomedica$6.48$0.46▼$2.04$30.11M0.686,718 shs224,800 shsGMTXGemini Therapeutics$53.17+4.0%$48.98$1.16▼$14.10$58.49M-0.12189,291 shs503,663 shsNEXINexImmune$0.00$0.02$0.00▼$7.05N/A1.966,478 shs235 shsSGTXSigilon Therapeutics$22.47$22.02$3.77▼$28.00$56.40M4.1262,902 shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANGNAngion Biomedica0.00%0.00%0.00%0.00%0.00%GMTXGemini Therapeutics+3.99%-1.38%+11.40%+16.17%+27.75%NEXINexImmune0.00%0.00%0.00%0.00%-100.00%SGTXSigilon Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANGNAngion BiomedicaN/AN/AN/AN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/ASGTXSigilon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANGNAngion Biomedica 0.00N/AN/AN/AGMTXGemini Therapeutics 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ASGTXSigilon Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANGNAngion Biomedica$2.30M0.00N/AN/A$1.32 per share0.00GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ANEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ASGTXSigilon Therapeutics$12.94M4.36N/AN/A$15.68 per share1.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANGNAngion Biomedica-$38.81MN/A0.00N/AN/AN/A-47.53%-40.55%N/AGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ANEXINexImmune-$32.34M-$18.54N/A∞N/AN/A-534.32%-213.72%8/5/2025 (Estimated)SGTXSigilon Therapeutics-$43.56M-$12.23N/AN/AN/A-171.29%-83.07%-38.17%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANGNAngion BiomedicaN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ASGTXSigilon TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANGNAngion BiomedicaN/A20.0020.00GMTXGemini TherapeuticsN/A71.4971.49NEXINexImmuneN/A0.660.66SGTXSigilon TherapeuticsN/A1.781.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANGNAngion Biomedica17.00%GMTXGemini Therapeutics75.42%NEXINexImmune9.85%SGTXSigilon TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipANGNAngion Biomedica19.70%GMTXGemini Therapeutics12.90%NEXINexImmune14.90%SGTXSigilon Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANGNAngion Biomedica330.11 million24.18 millionNot OptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableNEXINexImmune61.40 million1.19 millionNot OptionableSGTXSigilon Therapeutics622.51 million2.35 millionNot OptionableGMTX, NEXI, ANGN, and SGTX HeadlinesRecent News About These CompaniesRegenxbio expands MPS I gene therapy trial after first look at dataAugust 29, 2024 | pharmaphorum.comPLilly & Co Eli's Net WorthMay 1, 2024 | benzinga.comMCRB Seres Therapeutics, Inc.April 14, 2024 | seekingalpha.comBeam Therapeutics Inc.October 22, 2023 | wsj.comEli Lilly Concludes Acquisition Of Sigilon TherapeuticsAugust 14, 2023 | markets.businessinsider.comLilly Completes Acquisition of Sigilon TherapeuticsAugust 14, 2023 | finance.yahoo.comSGTX - Sigilon Therapeutics, Inc.August 1, 2023 | finance.yahoo.comInside Eli Lilly's Strategic Investment In Sigilon: An Opportunity OverlookedJuly 31, 2023 | msn.comSIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon ...July 21, 2023 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WMC, SGTX, AJX, IMNMJuly 18, 2023 | markets.businessinsider.comCanaccord Genuity Maintains Sigilon Therapeutics (SGTX) Buy RecommendationJuly 6, 2023 | msn.comSigilon Therapeutics (SGTX) Price Target Decreased by 6.27% to 48.28July 6, 2023 | msn.com5 big deal reports: Overstock snags Bed Bath & Beyond IP; Visa pays $1B for PismoJuly 3, 2023 | msn.comShares of Cambridge biotech Sigilon soar after company OKs Eli Lilly buyoutJune 30, 2023 | wickedlocal.comWLilly of the valley provides big bounce-back for Sigilon via T1D takeoverJune 30, 2023 | bioworld.comBSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sigilon Therapeutics, Inc. BuyoutJune 29, 2023 | benzinga.comEli Lilly to buy Sigilon Therapeutics on a massive premiumJune 29, 2023 | invezz.comIModerna Billionaire Set to Score 3,000% Gain on Tiny BiotechJune 29, 2023 | finance.yahoo.comEli Lilly and Company: Lilly to Acquire Sigilon TherapeuticsJune 29, 2023 | finanznachrichten.deHealth Care Company Eli Lilly Announces Acquisition of Sigilon TherapeuticsJune 29, 2023 | msn.comMedia Sentiment Over TimeGMTX, NEXI, ANGN, and SGTX Company DescriptionsAngion Biomedica NASDAQ:ANGNAngion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.Gemini Therapeutics NASDAQ:GMTX$53.17 +2.04 (+3.99%) As of 07/2/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.NexImmune NASDAQ:NEXI$0.0001 0.00 (0.00%) As of 07/2/2025 09:32 AM EasternNexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Sigilon Therapeutics NASDAQ:SGTXSigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
